DBV Technologies S.A. (DBVT) is a French biopharmaceutical company pioneering a new approach in the field of immunotherapy. Incorporated in 2002, DBV is headquartered in Montrouge, France with additional offices in Summit, New Jersey. Their mission is to safely alter the immune response by leveraging the skin’s natural properties, ultimately transforming the treatment of severe pediatric and adult food allergies, including peanut and milk, for which there are no approved treatments.
One of DBV’s standout developments is Viaskin, a patented epicutaneous immunotherapy (EPIT) platform. Unlike traditional immunotherapies, Viaskin allows the delivery of allergens via the skin without allowing them to reach the bloodstream, reducing the risk of severe systemic reactions. It consists of a patch applied onto the skin that slowly delivers micro-doses of specific allergens to progressively desensitize patients over time.
Their flagship product, Viaskin Peanut, targets peanut allergies, which can be potentially life-threatening. It represents a game-changing approach that can transform the lives of millions of people suffering from this condition. Viaskin Peanut is currently under review by the Food and Drug Administration (FDA) in the United States.
In addition to serving the needs in food allergy, DBV is also involved other auto-immune related research and development projects. For instance, the company is currently researching the application of EPIT in Esophagus Eosinophilic, a rare autoimmune disease that affects the pipe connecting the mouth and the stomach.
DBV Technologies operates under an Open-Innovation model and actively collaborates with pharmaceutical companies, biotech firms, academic institutions, and patient organizations worldwide. This collaborative effort ensures the exchange of ideas and expertise, which ultimately accelerates the development of innovative treatments.
The company is publicly listed and traded on both the Euronext Paris stock exchange (DBV) and on the Nasdaq Global Select Market in the United States.
As a committed player, DBV Technologies adheres to the highest ethical standards, ensuring patient safety and data integrity. Their efforts in creating groundbreaking treatments for previously unmet medical needs establish DBV Technologies as a unique and vital player in the biotech industry.